Intercalated kaolinite as an emerging platform for cancer therapy
- 13 Downloads
An innovative cancer therapy strategy regarding the interface engineering of kaolinite has been designed. The exposed silanol group facilitates more guest species with high dispersion on the supports. Mn3O4 magnetic nanoparticles are uniformly distributed on external surfaces of the KaolinC12N with the Al–O–Mn bond for the detection of the tumor microenvironment by T1-MRI; Doxorubicin (DOX) are loaded in the interlayer space with the electrostatic interaction for chemo-treating; and KI is coated on the outer layer of the nanocomposites based on the electrostatic interaction for thyroid cancer targeting. The synergetic effects and the treatment mechanism enhanced by the interface engineering, KI@DOX-Mn3O4-KaolinC12N can cause remarkably low cell viability (57%, 200 μg/mL), tumor shrinking (75%, 20 μg/kg), and accumulation into the tumor tissues. The novel kaolinite based drug delivery system is expected to incorporate imaging diagnosis, targeted therapy and drug delivery into one single system for postoperative residual thyroid cancer treatment and observation for metastasis of focal area.
Keywordskaolinite pillared drug delivery system thyroid cancer
Unable to display preview. Download preview PDF.
This work was supported by the National Natural Science Foundation of China (21878341, 51804343, 41572036, 51225403), the Strategic Priority Research Program of Central South University (ZLXD2017005), the Natural Science Foundation of Hunan Province (2018JJ3670), the Key R&D Program of Hunan Province (2017GK2251), and Hunan Provincial Science and Technology Project (2016RS2004, 2015TP1006).
- 21.Sun T, Zhang YS, Pang B, Hyun DC, Yang M, Xia Y. Angew Chem Int Ed, 2014, 48: 12320–12364Google Scholar